Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 43,930 Shares of Company Stock

Posted by Tyrone Williams on Nov 4th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the sale, the insider owned 160,913 shares in the company, valued at approximately $4,801,643.92. This represents a 21.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.38, for a total transaction of $4,365,788.28.
On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total transaction of $2,664,822.66.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total value of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.

Alamar Biosciences Price Performance

Shares of ALMR opened at $30.22 on Wednesday. Alamar Biosciences, Inc. has a 12 month low of $18.84 and a 12 month high of $39.61. The firm has a 50 day simple moving average of $30.49. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. On average, analysts forecast that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alamar Biosciences

Hedge funds have recently made changes to their positions in the company. Braidwell LP purchased a new position in shares of Alamar Biosciences in the second quarter valued at approximately $29,365,000. Wellington Management Group LLP purchased a new stake in shares of Alamar Biosciences during the second quarter worth approximately $12,407,000. State Street Corp purchased a new stake in shares of Alamar Biosciences during the second quarter worth approximately $3,930,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after purchasing an additional 10,461 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Alamar Biosciences in the 2nd quarter valued at $283,000.

Key Stories Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: For Q3 2026, Alamar reported a loss of $0.19 per share, beating the $0.22-per-share loss consensus, and revenue of $33.55 million. The company also raised its 2026 revenue guidance, a potentially supportive signal for its growth outlook. Alamar reports Q3 results and raises 2026 revenue guidance
Positive Sentiment: Alamar announced a scientific collaboration with GSK using its NULISA platform in a large-scale study of protein signatures across several disease areas. The partnership could raise the platform’s profile, though no financial terms were disclosed. Alamar partners with GSK on proteomic study
Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study focused on neurodegenerative diseases, with support from major research organizations. The project may showcase Alamar’s technology in a significant research effort; direct commercial impact was not specified. Alamar and Nightingale to lead UK Biobank study
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming disclosed sales totaling 187,636 shares across October 30 and November 2. Large-holder selling can weigh on sentiment, although the filings do not state the reason for the sales. SEC filing on shareholder transactions

Analyst Ratings Changes

A number of equities analysts have weighed in on ALMR shares. Weiss Ratings cut shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. lifted their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Stifel Nicolaus lifted their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $31.80.

Check Out Our Latest Stock Analysis on ALMR

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.